ArticleApplied microbiology and biotechnology2026
Untargeted metabolomics and in silico analysis identifies potential DNA gyrase inhibitors from an endophytic fungus Alternaria alternata P02PL2.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The escalating threat of multidrug-resistant (MDR) bacterial pathogens underscores the urgent need for novel antimicrobial agents. Here, we combined a one-strain many compounds (OSMAC) and untargeted metabolomics approaches to investigate the bioactivities and the chemical space of the endophytic fungus Alternaria alternata P02PL2, isolated from a medicinal plant, Sclerocarya birrea. The antibacterial activities were assessed against contemporary clinical isolates, MDR Pseudomonas aeruginosa 5625574, methicillin-resistant Staphylococcus aureus (MRSA) 5627679, and a collection culture of S. aureus ATCC 25923 for reference. We first tested for bioactivities across eight growth media to optimize the production of bioactive secondary metabolites. The bioactive fungal extract fractions exhibited minimum inhibitory concentrations (MICs) ranging from 0.25 to 0.5 mg/mL. This was followed by an untargeted metabolomics analysis, which identified 41 secondary metabolites. Virtual screening, molecular docking, and 200-ns molecular dynamics simulations targeting S. aureus and P. aeruginosa DNA gyrase revealed lead compounds with superior binding affinities (e.g., fluorescein -9.2 kcal/mol for P. aeruginosa; pyrrolo[1,2-a] pyrazine-1,4-dione, hexahydro -8.8 kcal/mol for S. aureus) compared to reference ligands. Binding free energy calculations highlighted strong affinities, with 5,7-dihydroxy-2-(4-hydroxyphenyl)-6,8-bis(3,4,5-trihydroxyoxan-2-yl)chromen-4-one (-42.16 kcal/mol) and fluorescein (-41.42 kcal/mol) outperforming the P. aeruginosa reference ligand evo (-19.80 kcal/mol) and 80s (-48.74 kcal/mol) leading for S. aureus. Per-residue energy decomposition and quantum chemical analyses further elucidated key interactions and reactivity profiles. These results position A. alternata P02PL2 as a promising source of DNA gyrase inhibitors to combat antimicrobial resistance. KEY POINTS: • A. alternata extracts inhibits S. aureus and Pseudomonas with MIC of 0.25-0.5 mg/mL • Inhibitors included Diketopiperazine (S. aureus), C-glycosyl flavone (Pseudomonas) • In silico analyses suggest the metabolites putatively inhibit bacterial DNA gyrase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.